The Acute Effects of Oleic Acid Enriched-diets on Lipids, Insulin Sensitivity and Serum Inflammatory Markers

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01124487

Enrollment

Registered

2010-05-17

Start date

2009-08-31

Completion date

2009-09-30

Last updated

2010-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lipid Profile

Keywords

fat, inflammation, lipids, total cholesterol, Triglycerides, insulin sensitivity

Brief summary

Objectives: To investigate the acute effects of olive oil, palm olein and lard on lipid profile, insulin sensitivity and inflammatory markers. Hypothesis: Different dietary fats will alter lipid profile, insulin sensitivity and inflammatory markers postprandially.

Detailed description

A randomized, single blind, crossover design was undertaken to test meals enriched with palm olein vs olive oil vs lard. Volunteers were asked to participate in three postprandial challenges, separated by at least 3-days. Subjects were provided a low fat meal(\<10g fat) the day before the intervention. Fasting blood was collected the next day and the subjects were instructed to consume test meals (50g high fat meal). Further venous blood was collected at 30 min, 1h, 2h, 3h and 4h postprandially. Primary outcome variable: Triacylglycerol (TAG) Secondary outcome variables: Insulin sensitivity (glucose, insulin), non esterified fatty acids (NEFA), inflammatory markers

Interventions

DIETARY_SUPPLEMENTThe acute effects of dietary fat on lipid profile, insulin sensitivity and inflammatory markers

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

MALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Age: 18-45 years * BMI : 18.5-30 kg/m\^2 * Healthy, men

Exclusion criteria

* medical history of cardiovascular disease, cancer, diabetes or chronic diseases * BMI \< 18.5 OR \> 30 kg/m\^2 * waist hip ratio \> 0.9 * total cholesterol \> 5.2 mmol/L * triacylglycerol (TAG) \> 2.2 mmol/L * current use of antihypertensive or lipid lowering medication

Design outcomes

Primary

Measure	Time frame
Triacylglycerol (TAG)	4 h

Secondary

Measure	Time frame
Insulin sensitivity (glucose, insulin), non-esterified fatty acids (NEFA), inflammatory markers	4 h

Countries

Malaysia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026